Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024
Longeveron (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company, has announced its participation in the Emerging Growth Virtual Conference scheduled for December 4-5, 2024. The company will present on December 5, 2024, from 12:00 to 12:30 p.m. ET.
The presentation will be accessible through the company's website under the 'Events and Presentations' section, with the webcast replay available for 180 days following the conference. Participants can submit questions in advance to Questions@EmergingGrowth.com or during the event.
Longeveron (NASDAQ: LGVN), un'azienda biotecnologica nel settore della medicina rigenerativa in fase clinica, ha annunciato la sua partecipazione alla Emerging Growth Virtual Conference prevista per il 4-5 dicembre 2024. L'azienda presenterà il 5 dicembre 2024, dalle 12:00 alle 12:30 ET.
La presentazione sarà accessibile attraverso il sito web dell'azienda nella sezione 'Eventi e Presentazioni', con la registrazione disponibile per 180 giorni dopo la conferenza. I partecipanti possono inviare domande in anticipo a Questions@EmergingGrowth.com o durante l'evento.
Longeveron (NASDAQ: LGVN), una empresa biotecnológica de medicina regenerativa en etapa clínica, ha anunciado su participación en la Emerging Growth Virtual Conference programada para el 4-5 de diciembre de 2024. La empresa presentará el 5 de diciembre de 2024, de 12:00 a 12:30 p.m. ET.
La presentación será accesible a través del sitio web de la empresa en la sección 'Eventos y Presentaciones', con la repetición de la transmisión disponible durante 180 días después de la conferencia. Los participantes pueden enviar preguntas con anticipación a Questions@EmergingGrowth.com o durante el evento.
Longeveron (NASDAQ: LGVN), 임상 단계 재생의학 생명공학 회사가 2024년 12월 4-5일에 예정된 Emerging Growth Virtual Conference에 참여한다고 발표했습니다. 회사는 2024년 12월 5일 오후 12시부터 12시 30분(ET)까지 발표할 예정입니다.
발표는 회사 웹사이트의 '이벤트 및 프레젠테이션' 섹션에서 접근 가능하며, 회의 후 180일 동안 웹캐스트 재방송이 가능합니다. 참가자는 Questions@EmergingGrowth.com에 미리 질문을 보내거나 행사 중에 질문을 제출할 수 있습니다.
Longeveron (NASDAQ: LGVN), une société de biotechnologie spécialisée en médecine régénérative en phase clinique, a annoncé sa participation à la Emerging Growth Virtual Conference prévue pour les 4 et 5 décembre 2024. La société fera sa présentation le 5 décembre 2024, de 12h00 à 12h30 (ET).
La présentation sera accessible via le site web de l'entreprise dans la section 'Événements et Présentations', avec la rediffusion du webinaire disponible pendant 180 jours après la conférence. Les participants peuvent soumettre des questions à l'avance à Questions@EmergingGrowth.com ou pendant l'événement.
Longeveron (NASDAQ: LGVN), ein biotechnologisches Unternehmen im Bereich der regenerativen Medizin in der klinischen Phase, hat seine Teilnahme an der Emerging Growth Virtual Conference angekündigt, die für den 4.-5. Dezember 2024 geplant ist. Das Unternehmen wird am 5. Dezember 2024 von 12:00 bis 12:30 Uhr ET präsentieren.
Die Präsentation wird über die Website des Unternehmens im Abschnitt 'Veranstaltungen und Präsentationen' zugänglich sein, wobei die Wiederholung des Webcasts für 180 Tage nach der Konferenz verfügbar ist. Teilnehmer können im Voraus Fragen an Questions@EmergingGrowth.com senden oder während der Veranstaltung stellen.
- None.
- None.
MIAMI, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in the Emerging Growth Virtual Conference taking place December 4-5, 2024.
Details for the Company’s presentation:
| Date: | December 5, 2024 |
| Time: | 12:00 – 12:30 p.m. ET |
The webcast for this conference presentation may be accessed at the “Events and Presentations” section of the Company’s website. A replay of the webcast will be available on the Longeveron website for 180 days following the conference.
Questions may be submitted in advance to Questions@EmergingGrowth.com or asked during the event.
About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B™, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B™ has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-BTM development programs have received five distinct and important FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.
Investor and Media Contact:
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com
FAQ
When is Longeveron (LGVN) presenting at the Emerging Growth Virtual Conference?
How can investors access Longeveron's (LGVN) presentation at the December 2024 Emerging Growth Conference?
How can investors submit questions for Longeveron's (LGVN) December 2024 conference presentation?
What type of company is Longeveron (LGVN)?
